Asymptomatic heterozygous Parkin/PINK1 mutation carriers show altered premotor–motor inhibition. A single l-dopa administration could partly reverse this alteration. These mutation carriers can serve as in vivo models to study pre-symptomatic stages of Parkinsonism.